All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2021-02-04T11:01:27.000Z

ASH 2020 | Practice-changing abstracts in myeloproliferative neoplasms

By Jean-Jacques Kiladjian, Alessandro M. Vannucchi, John Mascarenhas, Ruben A. Mesa, Tiziano Barbui, Norio Komatsu, Laura Michaelis, Haifa Kathrin Al-Ali, Steffen Koschmieder, Angela Fleischman
Feb 4, 2021
Share:

Bookmark this article

The world-leading experts in MPN shared the top abstracts from ASH 2020 that they believe could have the greatest impact on clinical practice.

In this document, you will find comments from the MPN Hub Steering Committee members on the impact of mutation for MPN development and progression as well as exciting results from studies using novel drugs for the treatment of myelofibrosis and polycythemia vera. Furthermore, the latest data exploring the optimized use of interferon alpha will be featured.

ASH 2020 | Practice-changing abstracts in myeloproliferative neoplasms

Did you miss ASH 2020? Download the resource below to view the practice-changing abstracts and the expert opinions from our Steering Committee.

Download Here


More about...
ASH 2020

Related articles

Add bookmark

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

The MPN Hub invited Stefan Constantinescu to give a presentation and chair a discussion on his research paper entitled ‘Secreted mutant calreticulins as rogue cytokines...

May 18, 2023
Add bookmark

Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms

The MPN Hub invited Stefan Constantinescu to give a presentation and chair a discussion on his research paper entitled...

May 18, 2023
Add bookmark

The future of JAK inhibition in myelofibrosis

During the last steering committee (SC) meeting that was held on April 20, 2022, the SC members discussed about the future of JAK inhibition in myelofibrosis. The session was chaired by John Mascarenhas...

Jul 22, 2022
Add bookmark

The future of JAK inhibition in myelofibrosis

During the last steering committee (SC) meeting that was held on April 20, 2022, the SC members discussed about the future of JAK inhibition in...

Jul 22, 2022

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox